Where does Agios Pharmaceuticals's cash flow data come from?

Every line is extracted from Agios Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$422.6M—	-$412.78M—	——	——	——
Depreciation and amortization	$5.26M-5.7%	$5.18M-8.4%	$5.28M-7.2%	$5.25M-12.0%	$5.58M-9.7%
Stock-based compensation	$56.73M+26.2%	$52.55M+22.7%	$49.33M+7.8%	$48.1M+10.1%	$44.97M+2.5%
Change in accounts receivable	$12.79M—	$6.47M—	$1.91M—	——	——
Change in inventories	$5.48M-16.1%	$5.3M-37.9%	$5.61M-38.8%	$6.91M-16.4%	$6.54M-44.1%
Change in accounts payable	——	——	——	——	——
Change in accrued liabilities	——	——	——	——	-$4.37M-264%
Change in other assets	——	——	——	$10.04M—	$3.84M—
Change in income taxes payable/receivable	——	——	——	——	——
Non-cash operating lease expense	$12.67M+7.8%	$12.43M+7.8%	$12.19M+7.7%	$11.97M+7.6%	$11.75M+7.6%
Change in operating lease liabilities	-$17.2M-11.6%	-$16.78M-11.8%	-$16.32M-11.3%	-$15.86M-10.7%	-$15.41M-10.1%
Net cash from operating activities	-$380.41M+5.2%	-$372.98M+4.3%	-$409.93M-24.5%	-$406M-32.4%	-$401.46M-33.5%
Capital expenditures	$4.32M+87.0%	$4.32M+156%	$4.16M+337%	$3.03M+236%	$2.31M+210%
Purchases of investments	$615.04M-58.3%	$641.76M-58.4%	$679.01M-52.7%	$1.5B+181%	$1.47B+176%
Proceeds from maturities/sales of investments	$1.04B+40.3%	$1.03B+26.3%	$931.12M+9.0%	$816.61M-3.7%	$737.92M-13.9%
Net cash from investing activities	$405.91M—	$377.18M—	——	——	——
Proceeds from issuance of common stock	$9.14M-10.4%	$8.68M-39.9%	$10.96M+4.9%	$9.16M-5.5%	$10.2M+15.5%
Net cash from financing activities	$9.14M-10.4%	$8.68M-39.9%	$10.96M+4.9%	$9.16M-5.5%	$10.2M+15.5%
Net increase (decrease) in cash	——	——	-$161.02M—	-$3.65M—	-$39.8M—
Income taxes paid	——	——	$45.36M+7,220%	$45.26M+24,766%	$43.86M+4,034%
Accretion (Amortization) of Discounts and Premiums, Investments	$6.99M-47.5%	$7.2M-50.3%	$11.06M+19.4%	$13.12M—	$13.31M—
Accrued expenses and other liabilities	——	——	——	——	-$4.37M-264%
Operating lease liabilities	-$17.2M-11.6%	-$16.78M-11.8%	-$16.32M-11.3%	-$15.86M-10.7%	-$15.41M-10.1%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	$10.04M—	$3.84M—
Operating lease right-of-use asset amortization	$12.67M+7.8%	$12.43M+7.8%	$12.19M+7.7%	$11.97M+7.6%	$11.75M+7.6%
Depreciation and amortization	$5.26M-5.7%	$5.18M-8.4%	$5.28M-7.2%	$5.25M-12.0%	$5.58M-9.7%
Net realized gains (losses)	$144K+700%	$118K-29.8%	$0-100%	$17K-90.6%	$18K-90.0%
Proceeds From Sale And Maturity Of Available For Sale Securities	$1.04B+40.3%	$1.03B+26.3%	$931.12M+9.0%	$816.61M-3.7%	$737.92M-13.9%
Proceeds from exercises of stock options and other stock issuances	$9.14M-10.4%	$8.68M-39.9%	$10.96M+4.9%	$9.16M-5.5%	$10.2M+15.5%
Accrued payables for capital expenditures	——	——	——	——	$538K+878%
Increase Decrease In Operating Lease Liability	-$17.2M-11.6%	-$16.78M-11.8%	-$16.32M-11.3%	-$15.86M-10.7%	-$15.41M-10.1%
Income Taxes Paid, Net	——	——	$45.36M+7,220%	$45.26M+24,766%	$43.86M+4,034%
Free cash flow	-$384.73M+4.7%	-$377.29M+3.6%	-$414.09M-25.4%	-$409.03M-33.0%	-$403.77M-33.9%
Free cash flow	-$384.73M+4.7%	-$377.29M+3.6%	-$414.09M-25.4%	-$409.03M-33.0%	-$403.77M-33.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Agios Pharmaceuticals's cash flow data come from?: Every line is extracted from Agios Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.